Latest Conference Coverage

CMSC 2020 Day 1: Brian Weinshenker, MD, on Emerging Treatment Options for NMOSD

Brian Weinshenker, MD presents his lecture titled, "Neuromyelitis Optica Spectrum Disorders: Emerging Treatment Options" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 1: Patricia Coyle, MD on Diagnosis, Clinical Course, and Long-Term Management of Progressive MS

Patricia Coyle, MD, delivers her lecture titled, "Progressive MS: Diagnosis, Clinical Course and Long-Term Management" as part of the 2020 CMSC Virtual Annual Meeting.

Evobrutinib Shows Long-Term Efficacy and Safety in Phase 2 Study

Evobrutinib, a highly selective BTK inhibitor for the treatment of relapsing multiple sclerosis, showed long-term safety and success in reducing annualized relapse rates.

Ocrelizumab Has Similar Effects in MS With Shorter Infusion Time

The Genentech agent, which is approved for patients with relapsing-remitting multiple sclerosis, showed no new safety signals in a comparison between conventional and shorter infusion times.

Ofatumumab Increases NEDA-3 Likelihood in MS Compared With Teriflunomide

Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.

The Importance of Interdisciplinary Care in MS

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.

Mark Freedman, MD: An Update on Stem Cell Research in MS

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.

Second Dose of Ubrogepant Is Safe and Effective in Acute Migraine

The study author, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of a pooled analysis of the ACHIEVE I and II studies of ubrogepant.

Brenda Banwell, MD: Current Perspectives on Pediatric MS Care and Research

The chief of the Division of Neurology at Children’s Hospital of Philadelphia spoke to the need for clinical trial evidence and research for the pediatric MS population.

Andrew Blumenfeld, MD: Long-Term OnabotulimuntoxinA Use in the COMPEL Study

The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.

Amy Sullivan, PsyD, ABPP: Interdisciplinary Care in MS

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.

Ofatumumab Shines in Pooled Comparative Analysis in Relapsing Multiple Sclerosis

The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.

Nusinersen Shows Efficacy in Infantile- and Late-Onset Spinal Muscular Atrophy

The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.

Steve Chung, MD: Cannabidiol in Tuberous Sclerosis Complex

The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.

Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.

BAN2401 Linked to Persistent Negative Amyloid PET in Alzheimer Disease

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.

Eteplirsen Slows Pulmonary Decline in Duchenne Muscular Dystrophy

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.

Nina Riggins, MD, PhD: The Effect of Dihydroergotamine Infusion Rates

The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes.

Steve Chung, MD: Perampanel's Effect on Insomnia in Patients With Epilepsy

The neurologist at Banner-University Medicine Neuroscience Institute discussed the findings of a study that suggest perampanel may improve insomnia by decreasing anxiety in patients with epilepsy.

Cenobamate Reduces Seizure Frequency Regardless of Concomitant AEDs

Treatment with SK Life Science’s cenobamate showed higher responder rates than placebo, regardless of baseline seizure frequency or disease duration.

Jeremy Payne, MD, PhD: The Lack of Progress for Telestroke

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute spoke to the need for data like that from the TELECAST study and how the COVID-19 pandemic might push telestroke care forward.

Bhooma Aravamuthan, MD, DPhil: Taking a Multi-Specialist Approach to Cerebral Palsy

The assistant professor of neurology at the University of Washington in St. Louis discussed the need for a systemic, multi-specialist approach to cerebral palsy and provided the main takeaways from her and her colleagues’ work.

Jeremy Payne, MD, PhD: The Need to Improve Telestroke Care

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute discussed how data from the TELECAST trial impact existing literature and the areas of improvement for the current use of telemedicine for stroke.

Fenfluramine-Reduced Seizure Frequency in Dravet Improves Executive Function

Treatment with fenfluramine was associated with greater seizure reduction, which in turn improved executive function over time in patients with Dravet syndrome.

Where Do Ubrogepant and the Gepant Class Fit in Migraine Care?

The director of the Montefiore Headache Center discussed recent study findings on ubrogepant and offered insight into the possible future of the gepant class in migraine.

Bhooma Aravamuthan, MD, DPhil: Improving Neurologists' Focus on Cerebral Palsy

The assistant professor of neurology at the University of Washington in St. Louis detailed the ­­factors that may contribute to these inconsistencies in cerebral palsy diagnosis and what role neurologists should play.

Ponesimod Displays Superiority in Relapsing MS Treatment

Janssen’s S1P receptor modulator ponesimod showed its superiority to teriflunomide on annualized relapse rates, fatigue symptoms, MRI activity, brain atrophy, and NEDA-3 in patients with relapsing multiple sclerosis.

Galcanezumab Has Significant Impact for Patients With Refractory Migraine

The FDA-approved anti-CGRP therapy from Eli Lilly demonstrated a significant ability to decrease monthly migraine days in patients who did not respond to previous medications.

Jeffrey Cohen, MD: Ofatumumab's Potential Role in MS Care

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the wide variety of clinical benefits observed with ofatumumab treatment and how it fits into the MS care landscape.

Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS

Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and Collateral subscales of the Expanded Disability Status Scale.